Efficacy of the Use of Vasopressin as a Primary Vasoconstrictor in Critically Ill Patients
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY
Current guidelines recommend the inititaion of noradrenaline and if shock is refractory, then vasopressin should be administered. Data indicate that the earlier use of vasopressin may improve survival. Two large randomized controlled trial failed to prove a survival benefit from the early use of vasopressin. The present study will investigate the effect of an early initiation protocol of vasopressin (as the first vasoconstrictor drug) on the degree of multiorgan failure improvement and also on the course of sepsis (if in septic patients) versus early initiation of noradrenaline as first vasoconstrictor drug in hemodynamically unstable patients.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• • Shock (mean arterial pressure \<65 mmHg) after initial resuscitation with fluids
Locations
Other Locations
Greece
General University Hospital of Larissa, Intensive Care Unit
RECRUITING
Larissa
Contact Information
Primary
Vasiliki Tsolaki, PhD, MD
vasotsolaki@yahoo.com
00306972804419
Time Frame
Start Date:2023-12-15
Estimated Completion Date:2026-01-31
Participants
Target number of participants:145
Treatments
Experimental: Vasopresin Group
Initiation of vasopressin as the first vasoactive agent (1 amp in 50 mlN/S) up to a maximum dose of 0.03 IU/min (2.3 ml/h). If the patient has MAP \<65 mmHg then noradrenaline will be started.
Active_comparator: Noradrenaline group
Initiation of noradrenaline first, up to 0,5 mcg/kg/min. If the patient has MAP \<65 mmHg vasopressin will be started (maximum dose of 0.03 IU/min (2.3ml/h)\]. If If the patient has MAP \<65 mmHg, noradrenaline will be further escalated.